Clinical Trials Logo
  1. Home
  2. Safety and Tolerability
  3. NCT03307512

PK and PD Profile of Dance 501 in Healthy, Non-diabetic Subjects With Mild to Moderate Asthma or COPD

Safety and Tolerability Clinical Trial

Official title:
Samba-AC: A Randomized, Open-Label, Cross-Over Study to Investigate the PK and PD Profiles of Dance 501 (Human Insulin Inhalation Solution and Inhaler) in Healthy Subjects and Non-Diabetic Subjects With Mild to Moderate Asthma or COPD

Clinical Trial Summary

This will be a randomized, open-label, active-controlled, single dose crossover study with either three or four treatment periods. Investigational treatment is with Dance 501 Human Insulin Inhalation Solution (Dance 501) and the comparator is Insulin Lispro (Humalog®).

Target population will be Non-Diabetic individuals with mild to moderate asthma or chronic obstructive pulmonary disease (COPD) and non-diabetic individuals without underlying lung disease (healthy subjects).

Clinical Trial Description

The PK and PD profile of Dance 501 (Human Insulin Inhalation Solution and Inhaler) will be compared to subcutaneous injection of insulin lispro. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT03307512
Study type Interventional
Source Dance Biopharm Inc.
Contact
Status Terminated
Phase Phase 2
Start date February 6, 2018
Completion date August 30, 2019
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT06000891 - A Trial Assessing Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ZP7570 Phase 1
Active, not recruiting NCT05997641 - Evaluating the Safety, Tolerability, and Pharmacokinetics of DF-003 in Healthy Subjects Phase 1
Completed NCT06181760 - A Study to Evaluate the Safety of Fenretinide in Healthy Volunteers Phase 1
Recruiting NCT05907382 - Safety, Tolerability of JMKX003002 in Phase 1 Study in Healthy Subjects Phase 1
Completed NCT01952548 - Study Comparing the Pharmacokinetics, Pharmacodynamics, and Safety of K-312 in Healthy Adult Volunteers Phase 1
Recruiting NCT06453824 - SAD Evaluation of Safety, Tolerability, PK, and PD of MDI-2517 in Healthy Participants Phase 1
Completed NCT05431634 - Multiple Dose Study to Determine Safety and Tolerability of ESK-001 in Healthy Participants Phase 1
Recruiting NCT06331884 - Phase 1 Study to Evaluate Safety, Tolerability and Pharmacokinetics/-Dynamics of AK1967 (Procizumab) Phase 1
Completed NCT03046589 - DP13 SAD & MAD in Healthy Male Subjects Phase 1
Recruiting NCT06079541 - Phase 1 Clinical Study of JMKX003142 Tablets Phase 1
Completed NCT05223660 - A Phase I Pharmacokinetics Study for KT07 Capsule Phase 1
Completed NCT01907867 - Pharmacokinetic Profile in Plasma and Epithelial Lining Fluid of Finafloxacin Phase 1
Completed NCT03809052 - A First in Human Study to Evaluate the Safety, Tolerability and PK of GB1211 in Healthy Subjects Phase 1
Completed NCT03853421 - Placebo-controlled Study to Determine the Safety and Tolerability of Subcutaneous Doses of Sevuparin Phase 1
Completed NCT03702231 - Response to the SHINGRIX Varicella Zoster Virus (VZV) Vaccine in Chronic Lymphocytic Leukemia (CLL) and CLL Treated With Bruton's Tyrosine Kinase Inhibitor (BTK-I) Phase 2
Completed NCT03685708 - HEPLISAV-B Hepatitis B Vaccine in Chronic Lymphocytic Leukemia (CLL) and CLL Treated With Bruton's-Tyrosine Kinase Inhibitor (BTK-I) Phase 2
Completed NCT03817346 - Study of Ascending Single Oral Dose of GT-002 in Healthy Volunteers Phase 1
Active, not recruiting NCT01226316 - Safety, Tolerability & Potential Anti-cancer Activity of Increasing Doses of AZD5363 in Different Treatment Schedules Phase 1
Completed NCT05451667 - Single-Ascending Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of YJ001 in Healthy Volunteers Phase 1
Completed NCT02029482 - Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ACT-128800 in Healthy Subjects Phase 1